Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clavulanic acid - Ocuphire Phrama

Drug Profile

Clavulanic acid - Ocuphire Phrama

Alternative Names: Clavulanic acid CR - Ocuphire Pharma; Clavulanic acid extended-release (Serdaxin) - Ocuphire Pharma; Clavulanic acid IR - Ocuphire Pharma; RX-10100; Serdaxin; Zoraxel

Latest Information Update: 29 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Revaax Pharmaceuticals
  • Developer National Institute of Neurological Disorders and Stroke; Rexahn Pharmaceuticals
  • Class 2 ring heterocyclic compounds; Antidepressants; Anxiolytics; Azetidines; Carboxylic acids; Erectile dysfunction therapies; Neuroprotectants; Oxazolidinones; Small molecules
  • Mechanism of Action Beta lactamase inhibitors; Dopamine release stimulants; Serotonin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Erectile dysfunction; Major depressive disorder

Highest Development Phases

  • Discontinued Anxiety disorders; Erectile dysfunction; Major depressive disorder; Neurodegenerative disorders; Parkinson's disease

Most Recent Events

  • 05 Nov 2020 Rexahn Pharmaceuticals has been merged with Ocuphire Pharma to form Ocuphire Pharma
  • 27 Jun 2014 Clavulanic acid - Rexahn is available for licensing as of 21 Mar 2014. http://www.rexahn.com/cms/
  • 21 Mar 2014 Discontinued - Phase-II for Erectile dysfunction in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top